Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
Part of paid clinical trials in Madison, Wisconsin.
- Sponsor
- University of Wisconsin, Madison
- Study ID
- NCT07706179
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- HR+/HER2+ Breast Cancer
- Metastatic Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Alisertib — DRUGAlisertib 40mg on days 1-7 of 21-day cycles for 4 cycles
Study Details
The goal of this clinical trial is to learn if alisertib in addition to usual care works to treat HR+/HER2+ breast cancer. The main questions it aims to answer are: * Does alisertib stop the communication between HR and HER2? * Are there genetic markers that predict how well someone's cancer will respond to alisertib? Participants will receive alisertib in addition to their usual care.
Key Dates
- First listed
- Jul 15, 2026
- Start date
- Aug 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Alisertib plus standard of careParticipants receive alisertib in addition to usual care
Primary Outcome Measure
Clinical benefit defined as partial tumor response (PR) [ Time Frame: 12 weeks ]
Central Contacts
- Cancer Connect800-622-8922
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53705 |
Find similar trials in Madison, WI
By condition
By specialty
By research site
Related Studies
- Every Day Counts: A Lifestyle Program for Women With Metastatic Breast CancerRecruiting · Medical College of Wisconsin · Maywood, Illinois
- Evaluation of PSMA in HER2- AR+ Metastatic Breast CancerPHASE2 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPHASE1 · Recruiting · Relay Therapeutics, Inc. · Tucson, Arizona
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.PHASE3 · Recruiting · BriaCell Therapeutics Corporation · Phoenix, Arizona